Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

A-GCB); manufacturing and commercialisation including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialisation and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

The following are trademarks of Shire or companies within the Shire Group which are the subject of trademark registrations in certain territories:

ADDERALL XR(R) (mixed salts of a single-entity amphetamine)

ADDERALL(R) (mixed salts of a single-entity amphetamine)

CALCICHEW(R) range (calcium carbonate with or without vitamin D3)

CARBATROL(R) (carbamazepine) extended-release capsules

DAYTRANA(TM) (methylphenidate transdermal system)

ELAPRASE(R) (idursulfase)

FOSRENOL(R) (lanthanum carbonate)

INTUNIV(TM) (guanfacine) extended release

LIALDA(TM) (mesalamine)

MEZAVANT(R) (mesalazine)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release:

3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK))

COMBIVIR (lamivudine) (trademark
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... Jan. 11, 2011 SeqWright Inc., a world-wide ... continues to make significant strides to position itself ... 2011. SeqWright,s ongoing success can be attributed to ... demands and by investing in key genomics technologies. ...
... and NASHVILLE, Tenn., Jan. 11, 2011 AstraZeneca (NYSE: ... (SCRI), an international leader in advancing therapies for cancer ... lead the clinical development of a novel targeted oncology ... major cause of mortality globally; accounting for 7.4 million ...
... York, NY, 10 January 2011 Elsevier ... Diamond, Diamond-Like Materials, Carbon Nanotubes and Nitrides, will occur ... Elsevier organized conference discusses the significant improvements in material ... over the past few years. The improvements have lead ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... global climate change to cut food supplies. But these ... between increasing temperature and air pollution specifically ozone ... new study involving researchers at MIT shows that these ... to take both warming and air pollution into account ... detail at global production of four leading food crops ...
Breaking Biology News(10 mins):Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... BOSTON--Scientists at Dana-Farber Cancer Institute have uncovered the mechanism ... cancer cells, DNA with potent drugs while simultaneously preventing ... reported in the Aug. 14 issue of Molecular ... in clinical trials of compounds that force cancer cells ...
... toxin in an amphibian a 60 amino acid neurotoxin found ... may help shed more light into both the evolution of ... protein toxins have been identified in many vertebrate animals, including ... amphibians or birds. In the case of poisonous amphibians, like ...
... San Antonio Tao Weitao, a researcher in the College ... at San Antonio is making great strides in a project ... Area Foundation. The professor in the South Texas Center ... a soil-dwelling bacterium that threatens the health of military personnel ...
Cached Biology News:Study supports DNA repair-blocker research in cancer therapy 2Study supports DNA repair-blocker research in cancer therapy 3UTSA biology researchers demystify elusive war zone bacterium 2
... operate as a Voltage Clamp, as a Current ... electrophysiology research applications. Performance in any one mode ... • This amazing instrument is ... capabilities of Digital Signal Processing (DSP) integrated circuit ...
... Identical to the DH-2000, but comes with ... switch up to 5 Hz) The ... the continuous spectrum of deuterium and tungsten halogen ... combined-spectrum light source produces a powerful, stable output ...
... in g per ml and is determined from ... of a 1 mg per ml solution. ... agglutinate a 2% suspension of human blood group ... C. Preparation Note: Affinity purified by ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
Biology Products: